Description:

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION); ODM derived from: https://clinicaltrials.gov/show/NCT01541956

Link:

https://clinicaltrials.gov/show/NCT01541956

Keywords:
Versions (1) ▾
  1. 1/19/19
Copyright Holder:
see on clinicaltrials.gov
Uploaded on:

January 19, 2019

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes NCT01541956

Eligibility Type 2 Diabetes NCT01541956

Inclusion Criteria
chinese t2d patients who are inadequate controlled (6.5 %< hba1c ≤9%) by metformin (≥750mg/d but ≤1000mg/d, ≥12 weeks),
Exclusion Criteria
type 1 diabetes and secondary diabetes
acute metabolic diabetic complications within the past 3 months.
acute infections which may influence glucose level.
evidence of significant chronic diabetic complications,
clinically significant renal impairment and hepatic impairment patients, including history of cirrhosis or chronic hepatitis,
fpg > 270 mg/dl (15 mmol/l)
any of the following disease within the past 6 months: myocardial infarction (mi); coronary artery bypass surgery or percutaneous coronary intervention; unstable angina or stroke; congestive heart failure (chf)
other protocol-defined inclusion/exclusion criteria may apply